| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics AG | Executive VP, Head of R&D | Common Shares | 52.4K | $3.27M | $62.50 | Dec 6, 2021 | Direct |
| iTeos Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 24.2K | Jun 11, 2024 | Direct | ||
| CRISPR Therapeutics AG | Executive VP, Head of R&D | Restricted Stock Units | 13.3K | Dec 3, 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| ITOS | iTeos Therapeutics, Inc. | Jun 11, 2024 | 1 | $0 | 4 | Jun 13, 2024 | Director |
| ITOS | iTeos Therapeutics, Inc. | Jun 13, 2023 | 1 | $0 | 4 | Jun 15, 2023 | Director |
| ITOS | iTeos Therapeutics, Inc. | Jun 9, 2022 | 1 | $0 | 4 | Jun 10, 2022 | Director |
| CRSP | CRISPR Therapeutics AG | Dec 3, 2021 | 3 | -$872K | 4 | Dec 7, 2021 | Executive VP, Head of R&D |
| CRSP | CRISPR Therapeutics AG | Oct 15, 2021 | 1 | $0 | 4 | Oct 18, 2021 | Executive VP, Head of R&D |
| ITOS | iTeos Therapeutics, Inc. | Jun 17, 2021 | 1 | $0 | 4 | Jun 21, 2021 | Director |